Point of Care Nano-Tech Stock (OTC: PCNT)

Point of Care Nano-Tech (OTC:PCNT) Stock, Quote.Headers.trade-ideas

Point of Care Nano-Technology Inc is in the business of Licensing of Pet Food product.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ACGL

ACLS

ACRE

ADBE

ADSK

AGRO

AIQUY

AJMPF

ALGT

APAM

APTO

APTV

ARDX

ASMIY

ATVI

AWWI

AXAHF

AXAHY

AZNCF

BABA

BANF

BHLB

BMTC

BNDSY

BRBR

BXMT

CACI

CBRE

CBSH

CDAY

CHGS

CHRYY

CIVB

CMRE

COHU

CROX

CRTX

DIOD

EFSC

ELTZ

ENLAY

ENTG

EPAY

ESKYF

ESSYY

Eaton Vance Tax-Managed Diversified Equity

Eaton Vance Tax-Managed Global Diversified Equit

Stocks That Hit 52-Week Highs On Friday

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers & Shakers

General

ABCP

AEMD

AFTM

AGFAF

ALTAF

AMRK

ANDR

APAFF

ARXXL

ASPCF

BLOZF

BOSQF

BOTH

BSRC

BTCY

BTSC

BVLDF

BVNNF

CADMF

CBLRF

CLIRF

CLOW

CMGHF

CNBX

CNONF

CONN

COTE

CPNFF

CRNT

CTRM

CTVIF

CWBHF

DAUGF

DOGZ

ELGX

ENDV

ENRT

EVIO

FAMI

FCGD

GALOF

GCFB

GFTX

GGBXF

GLBS

GOSS

GRPBF

GTEC

HEMP

HHPHF

HNSBF

IGRW

INAP

IQST

JILL

JUTOY

KGET

KOPN

LATF

LIXT

LQDA

LTMCF

MDCN

MMJJF

MOGLF

NMHLY

NMKEF

NSUPF

NVSGF

NXTTF

NZRIF

OTEL

OTOW

OZSC

PAOTF

PHUN

PIXY

PMTS

PRRE

PSIX

PTOTF

QRTEA

QRTEB

RETC

RGLSF

RNSFF

SCNNF

SEED

SHLO

SNAVF

SNIRF

SXTC

TCHH

TISUQ

TLRY

Stocks That Hit 52-Week Lows On Tuesday

POINT OF CARE NANO TECH by Point of Care Nano-Technology, Inc.

Point of Care Nano-Technology Inc

Loop Capital analyst Alton Stump maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Hold and lowers the price target from $50 to $45.

Price Target

Analyst Ratings

CBRL

Loop Capital Maintains Hold on Cracker Barrel Old, Lowers Price Target to $45

WIIM

CHWY

Chewy shares are trading lower after the company announced the public offering of shares by a selling stockholder and a concurrent share repurchase.

Biotech

BNTX

Pfizer And BioNTech Receive Positive CHMP Opinion For Omicron KP.2-Adapted COVID-19 Vaccine In EU, Awaiting European Commission Authorization To Ship

Morgan Stanley analyst Ravi Shanker downgrades FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Equal-Weight to Underweight and lowers the price target from $215 to $200.

Downgrades

Morgan Stanley Downgrades FedEx to Underweight, Lowers Price Target to $200

Ahead of the 2024 presidential election, the front yard of Warren Buffett in Omaha, Nebraska, could play a pivotal role in shaping the outcome.
What Happened: In Nebraska's 2nd Congressional District, a single electoral vote could be crucial. Neighbors are closely watching to see if a blue-dot sign appears outside Buffett's home. These signs, part of a grassroots effort, symbolize Democratic solidarity in a predominantly Republican area, The Wall Street Journal <a href="https://www.wsj.com/us-news/blue-dot-signs-warren-buffett-presidential-race-a9a26579">report</a> on Friday.
Buffett's history of supporting Barack Obama and Hillary Clinton has raised hopes among Democrats. One neighbor even sent Buffett a handwritten letter urging him to display a blue-dot sign. His daughter, Susan Buffett, already has two signs in her yard.
The blue-dot campaign was initiated by Jason Brown, who lives near Buffett. Inspired by the Democratic National Convention, Brown's idea has led to thousands of signs being distributed across Omaha. The signs are especially concentrated in Buffett's upscale neighborhood.
See Also: <a href="https://www.benzinga.com/news/24/09/40950674/data-scientist-who-called-2020-election-correctly-says-its-gone-from-drastic-landslide-in-trumps-dir?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist Who Called 2020 Election Correctly Says Its Gone From &#8216;Drastic Landslide In Trump&#8217;s Direction To A drastic landslide For Harris&#8217;</a>
Brown and his wife, Ruth Huebner-Brown, have distributed over 5,000 signs and plan to produce more. They request a $10 contribution to cover costs and pledge to donate any profits. Despite the grassroots effort, Buffett has not commented on whether he will display a sign.
Why It Matters: The influence of Warren Buffett in political circles has been significant over the years. In 2017, Buffett surprisingly <a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr">expressed support for Donald Trump'</a>s cabinet choices, indicating his pragmatic approach to politics. This bipartisan stance adds weight to his potential endorsement in the current election.
Recently, Elon Musk speculated that this time, Buffett might be <a href="https://www.benzinga.com/general/politics/17/01/8927406/trumps-newest-unlikely-ally-warren-buffett">positioning for a Kamala Harris win</a>, given his $277 billion cash reserve. This speculation comes amid a divided business community, with hedge fund manager John Paulson warning of a market exit if Harris wins. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump In Trouble: Vice President Harris Has Record 6-Point Lead In 2024 Election Poll After Debate, Posts Highest Rankings In Key Demographics</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Trump Vs. Harris: Will Warren Buffett Display A Blue Or Red Dot In His Front Yard? Neighbors Wait To See Who The Oracle Of Omaha Is Supporting

The European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy&nbsp;(semaglutide 2.4 mg) label.
The label <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=170500" rel="noreferrer noopener">update</a> incorporates data showing that Wegovy, when added to the standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40813963/ozempic-maker-novo-nordisk-touts-encouraging-data-from-new-obesity-pill-showing-double-weight-los" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy</a>
Heart failure affects at least 64 million people worldwide and is especially prevalent in obese and/or type 2 diabetes patients.
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure, comprising approximately 50% of all heart failure cases.
The positive opinion is based on the results from the STEP HFpEF and STEP HFpEF-DM trials.
In both trials, Wegovy&nbsp;demonstrated greater reductions in heart failure-related symptoms, improvements in physical limitations, and weight loss compared to placebo.
The label update also incorporates data that showed that participants receiving Wegovy&nbsp;achieved a greater increase in exercise function, as measured by the difference in 6-minute walking distance (6MWD) from baseline to week 52, compared to those receiving placebo.
The recommendation to incorporate the data from the STEP HFpEF trials adds to the recent Wegovy&nbsp;EMA label update, which included data from the SELECT landmark trial to reflect the risk reduction of heart attack, stroke, and cardiovascular death.
With the positive opinion from the CHMP, Novo Nordisk expects implementation of the EU label update shortly, following a linguistic review process by the EMA.
As communicated earlier this year, Novo Nordisk will resubmit to the FDA in 2025 to include data from the STEP HFpEF trials in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40229407/novo-nordisk-withdraws-wegovy-fda-heart-failure-submission-terminates-development-of-two-early-st" rel="noreferrer noopener">Wegovy&nbsp;label in the U.S</a>.
In its quarterly earnings report, Novo Nordisk announced that it had submitted the Wegovy STEP HFpEF trials data for regulatory review in the U.S. and EU in January 2024. However, following discussions with the FDA, the company withdrew the submission.
Novo Nordisk said it plans to resubmit the file in early 2025, incorporating additional data, including findings from the kidney outcomes trial for its once-weekly injectable semaglutide 1.0 mg.
Price Action: NVO stock is down 0.42% at $134.32 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa" target="_blank" rel="noreferrer noopener">Abbott Laboratories&#8217; Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst</a>.</li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

Health Care

European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure

Morgan Stanley analyst Dara Mohsenian downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and maintains the price target from $185 to $185.

Morgan Stanley Downgrades PepsiCo to Equal-Weight, Maintains Price Target to $185

ATNM

Actinium Pharmaceuticals Publishes Phase 3 SIERRA Trial Results Of Iomab-B In Journal Of Clinical Oncology, Highlights Success In Achieving Complete Remission And Event-Free Survival

Morgan Stanley analyst Rashad Kawan maintains Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) with a Overweight and raises the price target from $9.9 to $10.95.

Morgan Stanley Maintains Overweight on Haleon, Raises Price Target to $10.95

Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) has been outperforming its dog-themed meme coin rivals, prompting calls for a surge to $10 billion and beyond.
What Happened: Pseudonymous crypto trader SomSpencer declared the arrival of the "meme season" in the crypto market, emphasizing the importance of PEPE as a key indicator. 
He stated that the meme coin has broken out and described Pepe as "the &#8220;meme index" for this crypto cycle, suggesting that its performance is a reliable indicator of the market&#8217;s risk appetite.
The trader <a href="https://x.com/SomSpencer1771/status/1836790093975031916">anticipates</a> PEPE to set new all-time highs in the current quarter, possibly before the election. He also predicts a significant liquidity shift from PEPE as it approaches a $10B billion market cap, with liquidity likely to rotate into midcaps and microcaps.
He concluded by stating, "No one is bullish enough. It&#8217;s time for an up-only market."
Another trader <a href="https://x.com/cryptojourneyrs/status/1836868278943371341">predicts</a> Pepe to overtake Shiba Inu based on Pepe&#8217;s market cap:trading volume ratio.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40876130/dogecoin-millionaire-highlights-pepe-and-dogecoin-as-two-biggest-meme-narratives-for-2025-">&#8216;Dogecoin Millionaire&#8217; Highlights Pepe and Dogecoin As &#8216;Two Biggest Meme Narratives For 2025,&#8217; Shiba Inu, Floki To Follow</a>
Why It Matters: IntoTheBlock data shows a 231.4% increase in large transaction volume and a 33.5% rise in daily active addresses. Transactions greater than $100,000 increased from 80 to 255 in the past two days.
Pepe's seven-day and 30-day gains stand at 13% and 8%, respectively. It has outperformed its rivals Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), up 3% and 6% over the past 30 days. In the past seven days, DOGE and SHIB are up 1% and 6%.
Pepe&#8217;s 24-hour trading volume at $1.7 billion exceeds that of both Dogecoin ($741.5 million) and Shiba Inu ($405 million) combined.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40881260/trader-shares-3-contrarian-takes-trump-meme-coin-an-obvious-buy-and-these-2-cryptos-are-de">Trader Shares &#8216;3 Contrarian Takes:&#8217; TRUMP Meme Coin &#8216;An Obvious Buy&#8217; And These 2 Cryptos Are &#8216;Deep Value&#8217; And Will Be &#8216;Outperforming Soon&#8217;</a></li>
</ul>

$DOGE

$PEPE

$SHIB

Pepe Leapfrogs Dogecoin, Shiba Inu In 30-Day Gains, Trading Volume: 'No One Is Bullish Enough,' Says Trader

CHPT

ChargePoint Says It Has Secured NEVI Award Funding To Proliferate EV Charging On California Highways

Asset Sales

NovaBay Pharmaceuticals Reaches Definitive Deal To Sell Avenova Assets For $9.5M, Expected To Close Q4 2024

Kopin Corporation Announces Pricing Of $27M Public Offering Of Common Stock And Pre-funded Warrants; Closing Of The Offering Is Expected To Occur On Or About September 23

Global Engine Group Announces Pricing Of $8M Initial Public Offering At Public Offering Price Of $4.00 Per Share

Across the recent three months, 4 analysts have shared their insights on Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.0, a high estimate of $45.00, and a low estimate of $45.00. Marking an increase of 6.31%, the current average surpasses the previous average price target of $42.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833694_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Essential Utilities's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Fowler</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jonathan Reeder</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Essential Utilities. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Utilities compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Essential Utilities's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Essential Utilities's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WTRG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Utilities analyst ratings.</a>
<h2>Unveiling the Story Behind Essential Utilities</h2>
Essential Utilities is a Pennsylvania-based holding company for us water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. Essential exited its noncore competitive water and energy services businesses.
<h3>Essential Utilities: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Essential Utilities's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.53%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: Essential Utilities's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Essential Utilities's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Essential Utilities's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.44%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Essential Utilities's debt-to-equity ratio is below the industry average at 1.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WTRG

4 Analysts Have This To Say About Essential Utilities

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Point of Care Nano-Tech

Point of Care Nano-Tech (PCNT) Forecast

Point of Care Nano-Tech (OTC:PCNT) Stock, Quote.Headers.trade-ideas